WO1996022736A1 - Embolizing system - Google Patents

Embolizing system Download PDF

Info

Publication number
WO1996022736A1
WO1996022736A1 PCT/US1996/000221 US9600221W WO9622736A1 WO 1996022736 A1 WO1996022736 A1 WO 1996022736A1 US 9600221 W US9600221 W US 9600221W WO 9622736 A1 WO9622736 A1 WO 9622736A1
Authority
WO
WIPO (PCT)
Prior art keywords
wire
elongate member
occlusion
particles
particle
Prior art date
Application number
PCT/US1996/000221
Other languages
French (fr)
Inventor
Toshiyuki Irie
Original Assignee
Scimed Life Systems, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scimed Life Systems, Inc. filed Critical Scimed Life Systems, Inc.
Priority to DE69632392T priority Critical patent/DE69632392T2/en
Priority to JP52287396A priority patent/JP3625837B2/en
Priority to EP96902111A priority patent/EP0805656B1/en
Publication of WO1996022736A1 publication Critical patent/WO1996022736A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/12Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
    • A61B17/12022Occluding by internal devices, e.g. balloons or releasable wires
    • A61B17/12099Occluding by internal devices, e.g. balloons or releasable wires characterised by the location of the occluder
    • A61B17/12109Occluding by internal devices, e.g. balloons or releasable wires characterised by the location of the occluder in a blood vessel
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/12Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
    • A61B17/12022Occluding by internal devices, e.g. balloons or releasable wires
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/12Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
    • A61B17/12022Occluding by internal devices, e.g. balloons or releasable wires
    • A61B17/12131Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device
    • A61B17/12181Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device formed by fluidized, gelatinous or cellular remodelable materials, e.g. embolic liquids, foams or extracellular matrices
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/12Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
    • A61B17/12022Occluding by internal devices, e.g. balloons or releasable wires
    • A61B17/12131Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device
    • A61B17/12181Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device formed by fluidized, gelatinous or cellular remodelable materials, e.g. embolic liquids, foams or extracellular matrices
    • A61B17/12186Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device formed by fluidized, gelatinous or cellular remodelable materials, e.g. embolic liquids, foams or extracellular matrices liquid materials adapted to be injected
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/12Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
    • A61B17/12022Occluding by internal devices, e.g. balloons or releasable wires
    • A61B2017/1205Introduction devices

Definitions

  • the present invention relates to an embolization system to block flow through a selected portion of a lumen. More particularly, the present invention relates to a system for introducing occlusion particles into the lumen of a blood vessel.
  • Embolization techniques are currently used to treat a variety of vascular and non-vascular diseases. Such diseases include arteriovenous malformations (AVMs), aneurysms, arteriovenous fistulas, and tumors.
  • AVMs arteriovenous malformations
  • Aneurysms arteriovenous fistulas
  • tumors There are currently three basic types of embolization systems in use. Those systems include embolic liquids, solid or solid-type agents, and particles. Embolic liquids include glues, (polymerizing agents), alcohols, and precipitating agents. Typical examples of embolic liquids are n-butylcyanoacrylate (n- BCA), ethyl alcohol and a precipitating agent sold by Ethicon of Germany under the tradename Ethibloc.
  • n- BCA n-butylcyanoacrylate
  • ethyl alcohol ethyl alcohol
  • precipitating agent sold by Ethicon of Germany under the tradename Ethibloc
  • the glues used as embolic liquids typically act to polymerize and harden in the vessel, thereby blocking or occluding the vessel into which they are introduced.
  • the alcohol or alcohol derivatives cause tissue damage to the vessel with resulting thrombus formation for occlusion.
  • Precipitating agents typically include a precipitating agent which is dissolved in infusion solution, but insoluble in a blood environment. When the infusion solution is introduced into the vessel, the precipitating agent precipitates out to cause occlusion.
  • Embolic liquids currently suffer from a number of disadvantages.
  • One disadvantage is that the liquids lack radiopacity. This makes it difficult to monitor the administration of the embolic liquids.
  • Another disadvantage is that the release of embolic liquids into the vessel to be occluded is difficult to control.
  • Solid agents when used in an embolization system, conventionally include occluding articles which are more discrete in nature than embolic liquids. Such articles have typically been formed of suture material or coils which are introduced into the vessel. The suture material (often silk), once released, assumes a convoluted shape within the vessel to cause thrombus formation and occlusion. A suture material occlusion system is discussed in the Ritchart et al.
  • solid agents also suffer from a number of disadvantages.
  • solid agents conventionally depend on thrombus formation in order to accomplish complete occlusion.
  • anti ⁇ coagulant agents if anti ⁇ coagulant agents are introduced into the bloodstream during surgery, the anticoagulant can substantially prevent thrombus formation thereby minimizing the occlusive effect of the solid agent.
  • the bodies' natural clot dissolving factors can cause recanalization.
  • the solid agent is a coil, it is either an insertion coil or a detachable coil. Insertion coils are introduced into the vessel by injection, or by being pushed through a base catheter. Once introduced into the vessel, they can become irretrievable and accurate delivery is difficult to control.
  • the coil When the coil is detachable, it must be particularly sized to fit the lumen of the vessel at the desired occlusion site. However, the size of the lumen of the vessel is difficult to predict. Therefore, it is not uncommon for the treating physician to move the solid agent (detachable coil) to the occlusion site only to find out that the dimensions of the detachable coil are inappropriate to the occlusion site in the vessel. This requires the physician to remove essentially the entire coil system and to re-insert the system with a different size detachable coil. It may be necessary to repeat this process a number of times before the properly sized solid agent is finally inserted in the lumen. Also, when removing an improperly sized detachable coil, it is not uncommon for the coil to engage the base catheter and unravel or unwind. Such a system is time consuming and inefficient.
  • a third conventional embolization system utilizes what are known as embolizing particles or occlusion particles.
  • Embolizing particles are typically smaller than solid occlusion agents and are suspended in solution. The solution is injected into the lumen to be occluded through a catheter.
  • Typical embolization particles are made of polyvinylalcohol (PVA) .
  • PVA polyvinylalcohol
  • the polyvinylalcohol particles are formed of a ground block of material which is put through a series of sieves to segregate the particles into various size categories.
  • the particles are suspended in solution and injected into the vessel through a delivery catheter.
  • conventional embolizing particles also suffer from a number of disadvantages. For example, in conventional systems, the particles cannot be easily retrieved once they are injected into the vessel.
  • An embolization system includes a catheter having a lumen.
  • An elongate member is insertable within the lumen of the catheter.
  • An occlusion particle has a receiving passageway therein for receiving the elongate member so the elongate member guides movement of the occlusion particle through the lumen of the catheter and into a vessel.
  • FIG. 2 is a cross-sectional view of an embolization system according to the present invention.
  • FIG. 3 is a cross-sectional view of the embolization system shown in FIG. 2, illustrating delivery of an occlusion particle into a vessel.
  • FIG. 4 is an enlarged and more detailed cross- section of the embolization system shown in FIGS. 2 and 3.
  • FIGS. 1, IA and IB illustrate a common problem with polyvinylalcohol (PVA) injection type embolization systems.
  • FIG. 1 shows a delivery catheter 10 residing in a vessel 11 and having a distal end 13.
  • Catheter 10 is carrying a PVA solution, or injectate, which includes a plurality of PVA particles 12. While PVA particles 12 are not typically perfect spheres, they are illustrated as spheres for the sake of simplicity in FIG. 1.
  • delivery catheter 10 is typically manipulated through vessel 11 so distal end 13 is proximate a desired occlusion site 14. When distal end 13 of delivery catheter 10 reaches occlusion site 14, the solution carrying PVA particles 12 is injected into the delivery catheter 10 and delivered to occlusion site 14.
  • PVA-type occlusion can also suffer from one of the problems commonly associated with discrete or solid-type occlusion devices.
  • thrombus formation can cause occlusion.
  • anticoagulant therapy may be administered. This therapy can substantially prevent thrombus formation.
  • the treating physician must inject more solution carrying PVA particles 12.
  • the need to deliver extra solution exacerbates the problem of potential reflux in vessel 11. Further, the body has natural clot dissolving factors which can begin to act on the thrombus. This can cause the thrombus at site 14 to dissolve over time.
  • FIG. IA taken along section lines 1A-1A in FIG. 1, shows the conventional cross-section of catheter 10 as being circular.
  • FIG. IB is taken along section lines IB-IB of FIG. 1 at a point where catheter 10 bends to access site 14.
  • the cross-section at the bent portion of catheter 10 is oval shaped. Since particles 12 are simply mixed in solution and injected through catheter 10, they are not typically aligned along a longitudinal axis of catheter 10. As the particles reach the oval cross- section of catheter 10, it is not uncommon for the particles to lodge against one another and the walls of catheter 10 to obstruct flow of the solution through catheter 10. This requires the physician to either insert some type of device into catheter 10 to dislodge the blockage, or it requires the physician to completely remove catheter 10 and insert another delivery catheter into vessel 11. This is time consuming, cumbersome and inefficient.
  • FIG. 2 is a cross-sectional view of an embolization system 18 according to the present invention.
  • Embolization system 18 includes delivery catheter 20, wire 22, occlusion particles 24, and pusher 26.
  • Embolization system 18 is shown inserted within the lumen of a vessel 28.
  • delivery catheter 20 is typically inserted into vessel 28 and its distal end 30 is manipulated to access an occlusion site in vessel 28.
  • Particles 24 each have a wire receiving passageway 32 therein. Particles 24 are mounted onto wire 22 by inserting wire 22 through the wire receiving passageway 32 in particles 24.
  • pusher 26 is also mounted onto wire 22.
  • pusher 26 is a catheter, or other tube, having a lumen 34 therein for receiving wire 22.
  • Pusher 26 has a distal end portion 36 which engages particles 24 as pusher 26 is advanced along wire 22.
  • Wire 22, particles 24, and pusher 26 are all advanced within delivery catheter 20 to distal end 30 of delivery catheter 20, proximate the site to be occluded.
  • Wire 22 has a curved portion 38 at its distal end.
  • the curved portion 38 is illustrated in FIG. 2 is a generally J-shaped or hook-shaped portion. Curved portion 38 serves to retain particles 24 on wire 22 until the treating physician desires to release a particle 24 from wire 22.
  • FIG. 3 illustrates the operation of embolization system 18 when the treating physician desires to release a particle 24 into vessel 28.
  • the treating physician advances pusher 26 along wire 22 until particles 24 engage curved portion 38 at the distal end of wire 22.
  • the treating physician then continues to advance pusher 26 over wire 22 causing the distal most particle 24 to abut curved portion 38 of wire 22.
  • wire 22 is formed of a resilient, shape-memory material, such as a super elastic metal.
  • Wire 22 can also be another suitable elongate member such as plastic (teflon) material or other resilient synthetic or natural material.
  • the treating physician continues to advance pusher 26 until a desired number of particles 24 are released from wire 22 into vessel 28.
  • the treating physician retracts pusher 26 along wire 22. This allows curved portion 38 of wire 22 to return to its original position (shown in phantom in FIG. 3). Once in its original curved position, curved portion 38 of wire 22 again serves to retain additional particles 24 on wire 22.
  • Particles 24 are preferably radiopaque particles, such as platinum, making them visible under fluoroscopy. This allows the physician to achieve a high degree of control in releasing a desired number of particles 24 into vessel 28. When the desired number of particles 24 have been released, the treating physician can very easily prevent additional particles 24 from being released by simply retracting pusher 26 on wire 22. Further, with the present invention, the treating physician can recover all particles 24 which are in delivery catheter 20 and which are still on wire 22. Recovering such particles is extremely difficult in prior art embolization systems in which an injectate solution is used.
  • FIG. 4 is an enlarged cross-sectional view of embolization system 18 according to the present invention.
  • FIG. 4 illustrates a number of preferred dimensions for items, in embolization system 18.
  • the inner diameter of particle 24 is designated by the letter A.
  • the outer diameter of particle 24 is designated by the letter B.
  • the length of particle 24 is designed by the letter C.
  • the inner diameter of pusher 26 is designated by the letter D.
  • the outer diameter of pusher 26 is designated by the letter E.
  • the inner diameter of delivery catheter 20 is designated by the letter F, and the outer diameter of delivery catheter 20 is designated by the letter G.
  • the inner diameter A of particle 24 is preferably just larger than the outer diameter of wire 22.
  • an occlusion particle 24 is defined as having an outer diameter B smaller than the inner diameter F of delivery catheter 20, an inner diameter A larger than the outer diameter of wire 22, and a length C less than approximately 1 cm.
  • outer diameter B of particle 24 is preferably less than 0.75 mm.
  • outer diameter B of particle 24 is between 0.2 mm and 0.75 mm.
  • length C of particle 24 is less than approximately 1.2 mm. In another preferred embodiment, length C of particle 24 is between 0.7 mm and 1.2 mm.
  • the inner diameter D of pusher 26 is larger than the outer diameter of wire 22, but must be smaller than the outer diameter B of particle 24.
  • the outer diameter E of pusher 26 must be smaller than the inner diameter F of delivery catheter 20.
  • delivery catheter 20 has an outer diameter G of 0.7 mm and an inner diameter F of 0.53 mm.
  • pusher 26 has an outer diameter E of .33 mm and an inner diameter D of .15 mm.
  • the inner diameter A of particle 24 is less than 3 mm.
  • any suitable method of mounting particles 24 onto wire 22 can be used.
  • a single unitary piece can be mounted onto wire 22 and cut, or divided, into discrete particles 24.
  • the discrete particles 24 can first be formed and then mounted individually, or in groups, onto wire 22.
  • the present embolization system 18 can be used in conjunction with chemotherapeutic drugs.
  • the material of particle 24 can be a polymeric substance.
  • the density of the material used to form particle 24 will, in some instances, be determined based on the technique to be used.
  • the particles can be made of a material having a density greater than blood or less than blood, depending on the requirements for the particular vasculature being embolized.
  • the present invention overcomes certain problems associated with occlusions based on thrombus formation. If thrombus formation does form part of the occlusive effect of particles 24, and anti-coagulant therapy is used, the treating physician can easily release additional particles 24 to obtain desired occlusion. This can be carefully monitored and controlled so that substantially no reflux occurs.
  • the present invention also provides an efficient technique and apparatus for aligning particles 24 generally along a longitudinal axis of delivery catheter 20.
  • Particles 24 cannot be released from wire 22 unless they are released at the distal end of wire 22, and then only when the treating physician advances pusher 26 to a sufficient extent to release the particles 24. This essentially precludes particles 24 from being dislodged within delivery catheter 20 at an undesirable position.
  • delivery catheter 20 does not become blocked by particles 24 lodging against one another and the lumen walls of catheter 20.
  • the J-shaped or hook-shaped distal end portion 38 of wire 22 allows the treating physician to release particles 24, but also helps to prevent intimal injury. Since the curved portion 38 is quite large and smoothly curved, it does not damage the interior surface of the vessel.
  • the controlled release of particles 24 accomplished by the present invention substantially reduces the incidence of reflux. Since the treating physician is capable of monitoring the precise amount of particles 24 released, that amount can be controlled and adjusted when distal flow is reduced due to partial occlusion of the vessel. This substantially eliminates problems associated with reflux.

Abstract

An embolizing system (18) includes a catheter (20) having a lumen, an elongate member (22), insertable within the lumen of the catheter (20), and an occlusion particle (24). The occlusion particle (24) has a receiving passageway (32) therein for receiving the elongate member (22) so the elongate member (22) guides movement of the occlusion particle (24).

Description

EMBOLIZING SYSTEM
BACKGROUND OF THE INVENTION
The present invention relates to an embolization system to block flow through a selected portion of a lumen. More particularly, the present invention relates to a system for introducing occlusion particles into the lumen of a blood vessel.
Embolization techniques are currently used to treat a variety of vascular and non-vascular diseases. Such diseases include arteriovenous malformations (AVMs), aneurysms, arteriovenous fistulas, and tumors. There are currently three basic types of embolization systems in use. Those systems include embolic liquids, solid or solid-type agents, and particles. Embolic liquids include glues, (polymerizing agents), alcohols, and precipitating agents. Typical examples of embolic liquids are n-butylcyanoacrylate (n- BCA), ethyl alcohol and a precipitating agent sold by Ethicon of Germany under the tradename Ethibloc. The glues used as embolic liquids typically act to polymerize and harden in the vessel, thereby blocking or occluding the vessel into which they are introduced. The alcohol or alcohol derivatives cause tissue damage to the vessel with resulting thrombus formation for occlusion. Precipitating agents typically include a precipitating agent which is dissolved in infusion solution, but insoluble in a blood environment. When the infusion solution is introduced into the vessel, the precipitating agent precipitates out to cause occlusion. Embolic liquids currently suffer from a number of disadvantages. One disadvantage is that the liquids lack radiopacity. This makes it difficult to monitor the administration of the embolic liquids. Another disadvantage is that the release of embolic liquids into the vessel to be occluded is difficult to control. The liquids must be released upstream of the site at which eventual occlusion is desired. Blood flow carries the embolizing liquid through the lumen of the vessel, and it is difficult to control the release of a proper amount of occlusive liquid into the vessel to insure that occlusion occurs at the desired site in the vessel. Solid agents, when used in an embolization system, conventionally include occluding articles which are more discrete in nature than embolic liquids. Such articles have typically been formed of suture material or coils which are introduced into the vessel. The suture material (often silk), once released, assumes a convoluted shape within the vessel to cause thrombus formation and occlusion. A suture material occlusion system is discussed in the Ritchart et al. U.S. Patent 4,994,069 issued February 19, 1991. Coils, or coil assemblies, used as solid occlusion agents are shown in the Sepetka U.S. Patent 5,234,437 issued August 10, 1993. The coils occlude the desired site in the vessel by posing a physical barrier to blood flow. This promotes thrombus formation at the desired site, which eventually occludes the vessel.
However, solid agents also suffer from a number of disadvantages. First, solid agents conventionally depend on thrombus formation in order to accomplish complete occlusion. However, if anti¬ coagulant agents are introduced into the bloodstream during surgery, the anticoagulant can substantially prevent thrombus formation thereby minimizing the occlusive effect of the solid agent. Additionally, the bodies' natural clot dissolving factors can cause recanalization. Further, when the solid agent is a coil, it is either an insertion coil or a detachable coil. Insertion coils are introduced into the vessel by injection, or by being pushed through a base catheter. Once introduced into the vessel, they can become irretrievable and accurate delivery is difficult to control. When the coil is detachable, it must be particularly sized to fit the lumen of the vessel at the desired occlusion site. However, the size of the lumen of the vessel is difficult to predict. Therefore, it is not uncommon for the treating physician to move the solid agent (detachable coil) to the occlusion site only to find out that the dimensions of the detachable coil are inappropriate to the occlusion site in the vessel. This requires the physician to remove essentially the entire coil system and to re-insert the system with a different size detachable coil. It may be necessary to repeat this process a number of times before the properly sized solid agent is finally inserted in the lumen. Also, when removing an improperly sized detachable coil, it is not uncommon for the coil to engage the base catheter and unravel or unwind. Such a system is time consuming and inefficient.
A third conventional embolization system utilizes what are known as embolizing particles or occlusion particles. Embolizing particles are typically smaller than solid occlusion agents and are suspended in solution. The solution is injected into the lumen to be occluded through a catheter. Typical embolization particles are made of polyvinylalcohol (PVA) . The polyvinylalcohol particles are formed of a ground block of material which is put through a series of sieves to segregate the particles into various size categories. The particles are suspended in solution and injected into the vessel through a delivery catheter. However, conventional embolizing particles also suffer from a number of disadvantages. For example, in conventional systems, the particles cannot be easily retrieved once they are injected into the vessel. In addition, it is very difficult to control precisely how much of the injectate is delivered. Further, typical PVA particles are in suspension and are therefore not typically well aligned as they travel through the catheter. Therefore, they can wedge together and substantially block the delivery catheter. This requires the treating physician to either remove the entire system, including the delivery catheter, and replace it with another system, or to take extra time to remove the blockage from the delivery catheter. Another major problem associated with injecting PVA particles to occlude a vessel is referred to as reflux. Essentially, as PVA is injected into the vessel, and as the vessel begins to close, the distal flow at the occlusion site becomes smaller. Therefore, less injectate is needed at the occlusion site. If too much solution is injected, and the distal flow cannot accommodate the extra injectate, then the flow becomes proximal and can occlude a lumen of a normal vessel at a proximal site. This problem essentially arises from the difficulty in controlling the amount of PVA particles injected into the vessel.
SUMMARY OF THE INVENTION An embolization system includes a catheter having a lumen. An elongate member is insertable within the lumen of the catheter. An occlusion particle has a receiving passageway therein for receiving the elongate member so the elongate member guides movement of the occlusion particle through the lumen of the catheter and into a vessel. BRIEF DESCRIPTION OF THE DRAWINGS FIGs. 1, IA and IB illustrate one common problem with prior art embolization systems.
FIG. 2 is a cross-sectional view of an embolization system according to the present invention.
FIG. 3 is a cross-sectional view of the embolization system shown in FIG. 2, illustrating delivery of an occlusion particle into a vessel.
FIG. 4 is an enlarged and more detailed cross- section of the embolization system shown in FIGS. 2 and 3.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
FIGS. 1, IA and IB illustrate a common problem with polyvinylalcohol (PVA) injection type embolization systems. FIG. 1 shows a delivery catheter 10 residing in a vessel 11 and having a distal end 13. Catheter 10 is carrying a PVA solution, or injectate, which includes a plurality of PVA particles 12. While PVA particles 12 are not typically perfect spheres, they are illustrated as spheres for the sake of simplicity in FIG. 1. In operation, delivery catheter 10 is typically manipulated through vessel 11 so distal end 13 is proximate a desired occlusion site 14. When distal end 13 of delivery catheter 10 reaches occlusion site 14, the solution carrying PVA particles 12 is injected into the delivery catheter 10 and delivered to occlusion site 14. It is difficult to predict the precise amount (both size of particles and number of particles required) of injectate needed to occlude vessel 11 at site 14. Also, it is difficult to precisely control the amount of injectate delivered to site 14. This results in a wide variety of problems, most of which were mentioned in the Background of the Invention portion of the present specification. In addition, PVA-type occlusion can also suffer from one of the problems commonly associated with discrete or solid-type occlusion devices. When the PVA particles 12 are delivered to site 14, thrombus formation can cause occlusion. However, during surgery, anticoagulant therapy may be administered. This therapy can substantially prevent thrombus formation. Thus, the treating physician must inject more solution carrying PVA particles 12. Due to the difficulty in controlling delivery of an accurate amount (size and number of particles) of the solution, the need to deliver extra solution exacerbates the problem of potential reflux in vessel 11. Further, the body has natural clot dissolving factors which can begin to act on the thrombus. This can cause the thrombus at site 14 to dissolve over time.
In accessing site 14, catheter 10 must commonly make a number of bends. FIG. IA, taken along section lines 1A-1A in FIG. 1, shows the conventional cross-section of catheter 10 as being circular. However, FIG. IB is taken along section lines IB-IB of FIG. 1 at a point where catheter 10 bends to access site 14. The cross-section at the bent portion of catheter 10 is oval shaped. Since particles 12 are simply mixed in solution and injected through catheter 10, they are not typically aligned along a longitudinal axis of catheter 10. As the particles reach the oval cross- section of catheter 10, it is not uncommon for the particles to lodge against one another and the walls of catheter 10 to obstruct flow of the solution through catheter 10. This requires the physician to either insert some type of device into catheter 10 to dislodge the blockage, or it requires the physician to completely remove catheter 10 and insert another delivery catheter into vessel 11. This is time consuming, cumbersome and inefficient.
FIG. 2 is a cross-sectional view of an embolization system 18 according to the present invention. Embolization system 18 includes delivery catheter 20, wire 22, occlusion particles 24, and pusher 26. Embolization system 18 is shown inserted within the lumen of a vessel 28.
In operation, delivery catheter 20 is typically inserted into vessel 28 and its distal end 30 is manipulated to access an occlusion site in vessel 28. Particles 24 each have a wire receiving passageway 32 therein. Particles 24 are mounted onto wire 22 by inserting wire 22 through the wire receiving passageway 32 in particles 24. When a sufficient number of particles 24 are loaded onto wire 22, pusher 26 is also mounted onto wire 22. In a preferred embodiment, pusher 26 is a catheter, or other tube, having a lumen 34 therein for receiving wire 22. Pusher 26 has a distal end portion 36 which engages particles 24 as pusher 26 is advanced along wire 22. Wire 22, particles 24, and pusher 26 are all advanced within delivery catheter 20 to distal end 30 of delivery catheter 20, proximate the site to be occluded. Wire 22 has a curved portion 38 at its distal end. The curved portion 38 is illustrated in FIG. 2 is a generally J-shaped or hook-shaped portion. Curved portion 38 serves to retain particles 24 on wire 22 until the treating physician desires to release a particle 24 from wire 22.
FIG. 3 illustrates the operation of embolization system 18 when the treating physician desires to release a particle 24 into vessel 28. When distal end 30 of delivery catheter 20 is positioned to access a desired occlusion site in vessel 28, the treating physician advances pusher 26 along wire 22 until particles 24 engage curved portion 38 at the distal end of wire 22. The treating physician then continues to advance pusher 26 over wire 22 causing the distal most particle 24 to abut curved portion 38 of wire 22.
In the preferred embodiment, wire 22 is formed of a resilient, shape-memory material, such as a super elastic metal. Wire 22 can also be another suitable elongate member such as plastic (teflon) material or other resilient synthetic or natural material. Thus, as the treating physician continues to advance pusher 26, the distal most particle 24 causes curved portion 38 of wire 22 to straighten from its curved portion shown in phantom in FIG. 3, along a path generally indicated by arrow 40, to a straightened position shown in FIG. 3. Once wire 22 is in the straightened position, the treating physician continues to advance pusher 26 until a desired number of particles 24 are released from wire 22 into vessel 28. When the treating physician has released a desired amount of particles 24 into vessel 28, the treating physician retracts pusher 26 along wire 22. This allows curved portion 38 of wire 22 to return to its original position (shown in phantom in FIG. 3). Once in its original curved position, curved portion 38 of wire 22 again serves to retain additional particles 24 on wire 22.
Particles 24 are preferably radiopaque particles, such as platinum, making them visible under fluoroscopy. This allows the physician to achieve a high degree of control in releasing a desired number of particles 24 into vessel 28. When the desired number of particles 24 have been released, the treating physician can very easily prevent additional particles 24 from being released by simply retracting pusher 26 on wire 22. Further, with the present invention, the treating physician can recover all particles 24 which are in delivery catheter 20 and which are still on wire 22. Recovering such particles is extremely difficult in prior art embolization systems in which an injectate solution is used.
FIG. 4 is an enlarged cross-sectional view of embolization system 18 according to the present invention. FIG. 4 illustrates a number of preferred dimensions for items, in embolization system 18. The inner diameter of particle 24 is designated by the letter A. The outer diameter of particle 24 is designated by the letter B. The length of particle 24 is designed by the letter C. The inner diameter of pusher 26 is designated by the letter D. The outer diameter of pusher 26 is designated by the letter E. The inner diameter of delivery catheter 20 is designated by the letter F, and the outer diameter of delivery catheter 20 is designated by the letter G.
The inner diameter A of particle 24 is preferably just larger than the outer diameter of wire 22. For the purpose of the present invention, an occlusion particle 24 is defined as having an outer diameter B smaller than the inner diameter F of delivery catheter 20, an inner diameter A larger than the outer diameter of wire 22, and a length C less than approximately 1 cm. In the preferred embodiment, outer diameter B of particle 24 is preferably less than 0.75 mm. In another preferred embodiment, outer diameter B of particle 24 is between 0.2 mm and 0.75 mm. Also, in the preferred embodiment, length C of particle 24 is less than approximately 1.2 mm. In another preferred embodiment, length C of particle 24 is between 0.7 mm and 1.2 mm.
The inner diameter D of pusher 26 is larger than the outer diameter of wire 22, but must be smaller than the outer diameter B of particle 24. The outer diameter E of pusher 26 must be smaller than the inner diameter F of delivery catheter 20. In the preferred embodiment, delivery catheter 20 has an outer diameter G of 0.7 mm and an inner diameter F of 0.53 mm. In addition, pusher 26 has an outer diameter E of .33 mm and an inner diameter D of .15 mm. However, while these are preferred embodiments, and while the remainder of system 18 must be sized accordingly, any suitable dimensions can be used. It is also preferred that the inner diameter A of particle 24 is less than 3 mm.
It should be noted that any suitable method of mounting particles 24 onto wire 22 can be used. For instance, a single unitary piece can be mounted onto wire 22 and cut, or divided, into discrete particles 24. In addition, the discrete particles 24 can first be formed and then mounted individually, or in groups, onto wire 22.
It should also be noted that while platinum is a preferred material for particles 24, other materials can be used. For instance, the present embolization system 18 can be used in conjunction with chemotherapeutic drugs. In that instance, it is beneficial to form particle 24 of radioisotope material which enhances the effectiveness of the chemotherapy, and which enhances the effectiveness of embolization on tumors. Also, the material of particle 24 can be a polymeric substance. Further, the density of the material used to form particle 24 will, in some instances, be determined based on the technique to be used. For example, the particles can be made of a material having a density greater than blood or less than blood, depending on the requirements for the particular vasculature being embolized. The present invention overcomes certain problems associated with occlusions based on thrombus formation. If thrombus formation does form part of the occlusive effect of particles 24, and anti-coagulant therapy is used, the treating physician can easily release additional particles 24 to obtain desired occlusion. This can be carefully monitored and controlled so that substantially no reflux occurs.
The present invention also provides an efficient technique and apparatus for aligning particles 24 generally along a longitudinal axis of delivery catheter 20. Particles 24 cannot be released from wire 22 unless they are released at the distal end of wire 22, and then only when the treating physician advances pusher 26 to a sufficient extent to release the particles 24. This essentially precludes particles 24 from being dislodged within delivery catheter 20 at an undesirable position. Thus, delivery catheter 20 does not become blocked by particles 24 lodging against one another and the lumen walls of catheter 20. It should also be noted that the J-shaped or hook-shaped distal end portion 38 of wire 22 allows the treating physician to release particles 24, but also helps to prevent intimal injury. Since the curved portion 38 is quite large and smoothly curved, it does not damage the interior surface of the vessel.
In addition, the controlled release of particles 24 accomplished by the present invention substantially reduces the incidence of reflux. Since the treating physician is capable of monitoring the precise amount of particles 24 released, that amount can be controlled and adjusted when distal flow is reduced due to partial occlusion of the vessel. This substantially eliminates problems associated with reflux.
Although the present invention has been described with reference to preferred embodiments, workers skilled in the art will recognize that changes may be made in form and detail without departing from the spirit and scope of the invention.

Claims

WHAT IS CLAIMED IS:
1. An embolization system including a catheter having a lumen, and characterized by: an elongate member, insertable within the lumen of the catheter; and an occlusion particle having a receiving passageway therein for receiving the elongate member so the elongate member guides movement of the occlusion particle.
2. The embolization system of claim 1 wherein the embolization system further comprises: a pusher, slidable relative to the elongate member within the lumen of the catheter to engage the occlusion particle and to move the occlusion particle relative to the elongate member.
3. The embolization system of claim 2 wherein the pusher comprises: a second elongate member having a receiving passageway so the pusher is slidable along the elongate member, the elongate member moving relative to the pusher within the receiving passageway.
4. The embolization system of claim 3 wherein the elongate member comprises a wire and wherein the pusher comprises: a tube having a lumen, the lumen sized large enough to slidably receive the wire and sized smaller than an outer dimension of the occlusion particle.
5. The embolization system of claim 4 wherein the pusher has a distal end portion for engaging the occlusion particles and pushing the occlusion particle along the wire so that the occlusion particle slides relative to the wire, the wire passing through the wire receiving passageway in the occlusion particle.
6. The embolization system of claim 5 wherein the slide receiving passageway comprises a bore defined by the occlusion particle, the bore being large enough to slidably receive the wire.
7. The embolization system of claim 1 wherein the occlusion particle is formed of radiopaque material.
8. The embolization system of claim 2 wherein the elongate member comprises: a retaining end portion for controllably retaining the occlusion particle on the elongate member.
9. The embolization system of claim 8 wherein the elongate member comprises a wire and wherein the retaining end portion comprises: a curved portion of the wire located generally at the distal end of the wire.
10. The embolization system of claim 9 wherein the wire comprises: a flexible shape memory material, the curved portion being flexible to release the occlusion particle and return to its curved shape.
PCT/US1996/000221 1995-01-27 1996-01-03 Embolizing system WO1996022736A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
DE69632392T DE69632392T2 (en) 1995-01-27 1996-01-03 Embolisation
JP52287396A JP3625837B2 (en) 1995-01-27 1996-01-03 Embolic device
EP96902111A EP0805656B1 (en) 1995-01-27 1996-01-03 Embolizing system

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37880895A 1995-01-27 1995-01-27
US08/378,808 1995-01-27

Publications (1)

Publication Number Publication Date
WO1996022736A1 true WO1996022736A1 (en) 1996-08-01

Family

ID=23494628

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1996/000221 WO1996022736A1 (en) 1995-01-27 1996-01-03 Embolizing system

Country Status (6)

Country Link
US (2) US5895411A (en)
EP (1) EP0805656B1 (en)
JP (1) JP3625837B2 (en)
CA (1) CA2207667A1 (en)
DE (1) DE69632392T2 (en)
WO (1) WO1996022736A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6312407B1 (en) 1995-06-05 2001-11-06 Medtronic Percusurge, Inc. Occlusion of a vessel
US6638293B1 (en) 1996-02-02 2003-10-28 Transvascular, Inc. Methods and apparatus for blocking flow through blood vessels

Families Citing this family (127)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE42625E1 (en) 1990-03-13 2011-08-16 The Regents Of The University Of California Endovascular electrolytically detachable wire and tip for the formation of thrombus in arteries, veins, aneurysms, vascular malformations and arteriovenous fistulas
US6083220A (en) 1990-03-13 2000-07-04 The Regents Of The University Of California Endovascular electrolytically detachable wire and tip for the formation of thrombus in arteries, veins, aneurysms, vascular malformations and arteriovenous fistulas
USRE42756E1 (en) 1990-03-13 2011-09-27 The Regents Of The University Of California Endovascular electrolytically detachable wire and tip for the formation of thrombus in arteries, veins, aneurysms, vascular malformations and arteriovenous fistulas
US5814062A (en) 1994-12-22 1998-09-29 Target Therapeutics, Inc. Implant delivery assembly with expandable coupling/decoupling mechanism
US6994689B1 (en) 1995-06-05 2006-02-07 Medtronic Vascular, Inc. Occlusion of a vessel
EP0951870A1 (en) * 1998-04-21 1999-10-27 Medicorp S.A. Device for aneurysma treatment
US6511492B1 (en) * 1998-05-01 2003-01-28 Microvention, Inc. Embolectomy catheters and methods for treating stroke and other small vessel thromboembolic disorders
FR2784580B1 (en) * 1998-10-16 2004-06-25 Biosepra Inc POLYVINYL-ALCOHOL MICROSPHERES AND METHODS OF MAKING THE SAME
US6333020B1 (en) * 1999-05-13 2001-12-25 Micro Therapeutics, Inc. Methods for treating AVM's using radio active compositions
US6238403B1 (en) 1999-10-04 2001-05-29 Microvention, Inc. Filamentous embolic device with expansible elements
US6602261B2 (en) 1999-10-04 2003-08-05 Microvention, Inc. Filamentous embolic device with expansile elements
US20030212022A1 (en) * 2001-03-23 2003-11-13 Jean-Marie Vogel Compositions and methods for gene therapy
DE60130743T2 (en) * 2000-03-24 2008-07-17 Biosphere Medical, Inc., Rockland MICROBALLS FOR ACTIVE EMBOLIZATION
US7033374B2 (en) * 2000-09-26 2006-04-25 Microvention, Inc. Microcoil vaso-occlusive device with multi-axis secondary configuration
US8083768B2 (en) 2000-12-14 2011-12-27 Ensure Medical, Inc. Vascular plug having composite construction
US6846319B2 (en) * 2000-12-14 2005-01-25 Core Medical, Inc. Devices for sealing openings through tissue and apparatus and methods for delivering them
US6623509B2 (en) * 2000-12-14 2003-09-23 Core Medical, Inc. Apparatus and methods for sealing vascular punctures
US6896692B2 (en) 2000-12-14 2005-05-24 Ensure Medical, Inc. Plug with collet and apparatus and method for delivering such plugs
US6890343B2 (en) * 2000-12-14 2005-05-10 Ensure Medical, Inc. Plug with detachable guidewire element and methods for use
EP1401338B1 (en) * 2001-05-29 2011-07-20 Microvention, Inc. Method of manufacturing expansile filamentous embolization devices
US20030014075A1 (en) * 2001-07-16 2003-01-16 Microvention, Inc. Methods, materials and apparatus for deterring or preventing endoleaks following endovascular graft implanation
US6911219B2 (en) * 2001-09-27 2005-06-28 Surgica Corporation Partially acetalized polyvinyl alcohol embolization particles, compositions containing those particles and methods of making and using them
US7131997B2 (en) * 2002-03-29 2006-11-07 Scimed Life Systems, Inc. Tissue treatment
US7462366B2 (en) 2002-03-29 2008-12-09 Boston Scientific Scimed, Inc. Drug delivery particle
US7094369B2 (en) * 2002-03-29 2006-08-22 Scimed Life Systems, Inc. Processes for manufacturing polymeric microspheres
US7053134B2 (en) * 2002-04-04 2006-05-30 Scimed Life Systems, Inc. Forming a chemically cross-linked particle of a desired shape and diameter
US20030204246A1 (en) * 2002-04-25 2003-10-30 Jack Chu Aneurysm treatment system and method
WO2003105917A2 (en) 2002-06-12 2003-12-24 Scimed Life Systems, Inc. Bulking agents
CN101919722A (en) 2002-07-31 2010-12-22 微温森公司 The vascular occluding device of three-part coaxial
US7842377B2 (en) 2003-08-08 2010-11-30 Boston Scientific Scimed, Inc. Porous polymeric particle comprising polyvinyl alcohol and having interior to surface porosity-gradient
US7449236B2 (en) * 2002-08-09 2008-11-11 Boston Scientific Scimed, Inc. Porous polymeric particle comprising polyvinyl alcohol and having interior to surface porosity-gradient
US8012454B2 (en) 2002-08-30 2011-09-06 Boston Scientific Scimed, Inc. Embolization
US7588825B2 (en) * 2002-10-23 2009-09-15 Boston Scientific Scimed, Inc. Embolic compositions
US7883490B2 (en) 2002-10-23 2011-02-08 Boston Scientific Scimed, Inc. Mixing and delivery of therapeutic compositions
DE10259411A1 (en) * 2002-12-19 2004-07-08 Forschungszentrum Karlsruhe Gmbh Medical clip and device for applying such a device
US7655048B2 (en) * 2003-04-02 2010-02-02 Furlow Jr Leonard T Materials and methods for soft tissue augmentation
US7678123B2 (en) 2003-07-14 2010-03-16 Nmt Medical, Inc. Tubular patent foramen ovale (PFO) closure device with catch system
US8480706B2 (en) 2003-07-14 2013-07-09 W.L. Gore & Associates, Inc. Tubular patent foramen ovale (PFO) closure device with catch system
US9861346B2 (en) 2003-07-14 2018-01-09 W. L. Gore & Associates, Inc. Patent foramen ovale (PFO) closure device with linearly elongating petals
US20050013870A1 (en) * 2003-07-17 2005-01-20 Toby Freyman Decellularized extracellular matrix of conditioned body tissues and uses thereof
US7976823B2 (en) * 2003-08-29 2011-07-12 Boston Scientific Scimed, Inc. Ferromagnetic particles and methods
US8852229B2 (en) * 2003-10-17 2014-10-07 Cordis Corporation Locator and closure device and method of use
US7361183B2 (en) * 2003-10-17 2008-04-22 Ensure Medical, Inc. Locator and delivery device and method of use
US7901770B2 (en) * 2003-11-04 2011-03-08 Boston Scientific Scimed, Inc. Embolic compositions
US7736671B2 (en) * 2004-03-02 2010-06-15 Boston Scientific Scimed, Inc. Embolization
US8173176B2 (en) 2004-03-30 2012-05-08 Boston Scientific Scimed, Inc. Embolization
US20050238870A1 (en) * 2004-04-22 2005-10-27 Marcia Buiser Embolization
US7311861B2 (en) 2004-06-01 2007-12-25 Boston Scientific Scimed, Inc. Embolization
US20060025802A1 (en) * 2004-07-30 2006-02-02 Sowers William W Embolic coil delivery system with U-shaped fiber release mechanism
US7918872B2 (en) 2004-07-30 2011-04-05 Codman & Shurtleff, Inc. Embolic device delivery system with retractable partially coiled-fiber release
US20060025801A1 (en) * 2004-07-30 2006-02-02 Robert Lulo Embolic device deployment system with filament release
US7879064B2 (en) 2004-09-22 2011-02-01 Micro Therapeutics, Inc. Medical implant
ATE448737T1 (en) 2004-09-22 2009-12-15 Dendron Gmbh DEVICE FOR IMPLANTING MICROWL COILS
US8425550B2 (en) 2004-12-01 2013-04-23 Boston Scientific Scimed, Inc. Embolic coils
US7858183B2 (en) * 2005-03-02 2010-12-28 Boston Scientific Scimed, Inc. Particles
US7727555B2 (en) * 2005-03-02 2010-06-01 Boston Scientific Scimed, Inc. Particles
US7963287B2 (en) * 2005-04-28 2011-06-21 Boston Scientific Scimed, Inc. Tissue-treatment methods
US8926654B2 (en) 2005-05-04 2015-01-06 Cordis Corporation Locator and closure device and method of use
US7674271B2 (en) * 2005-05-04 2010-03-09 InTailor Surgical, Inc. Endoluminal gastric ring and method
US8088144B2 (en) * 2005-05-04 2012-01-03 Ensure Medical, Inc. Locator and closure device and method of use
CN104815331A (en) 2005-05-09 2015-08-05 生物领域医疗公司 Compositions and methods using microspheres and non-ionic contrast agents
US7371251B2 (en) * 2005-06-02 2008-05-13 Cordis Neurovascular, Inc. Stretch resistant embolic coil delivery system with mechanical release mechanism
US20060276825A1 (en) * 2005-06-02 2006-12-07 Vladimir Mitelberg Stretch resistant embolic coil delivery system with mechanical release mechanism
US20060276830A1 (en) * 2005-06-02 2006-12-07 Keith Balgobin Stretch resistant embolic coil delivery system with mechanical release mechanism
US7819891B2 (en) * 2005-06-02 2010-10-26 Codman & Shurtleff, Inc. Stretch resistant embolic coil delivery system with spring release mechanism
US20060276827A1 (en) * 2005-06-02 2006-12-07 Vladimir Mitelberg Stretch resistant embolic coil delivery system with mechanical release mechanism
US7985238B2 (en) * 2005-06-02 2011-07-26 Codman & Shurtleff, Inc. Embolic coil delivery system with spring wire release mechanism
US20060276833A1 (en) * 2005-06-02 2006-12-07 Keith Balgobin Stretch resistant embolic coil delivery system with spring assisted release mechanism
US7799052B2 (en) * 2005-06-02 2010-09-21 Codman & Shurtleff, Inc. Stretch resistant embolic coil delivery system with mechanical release mechanism
US7708754B2 (en) 2005-06-02 2010-05-04 Codman & Shurtleff, Pc Stretch resistant embolic coil delivery system with mechanical release mechanism
US7377932B2 (en) * 2005-06-02 2008-05-27 Cordis Neurovascular, Inc. Embolic coil delivery system with mechanical release mechanism
US7811305B2 (en) * 2005-06-02 2010-10-12 Codman & Shurtleff, Inc. Stretch resistant embolic coil delivery system with spring release mechanism
US7371252B2 (en) 2005-06-02 2008-05-13 Cordis Neurovascular, Inc. Stretch resistant embolic coil delivery system with mechanical release mechanism
US7819892B2 (en) 2005-06-02 2010-10-26 Codman & Shurtleff, Inc. Embolic coil delivery system with spring wire release mechanism
US7367987B2 (en) * 2005-06-02 2008-05-06 Cordis Neurovascular, Inc. Stretch resistant embolic coil delivery system with mechanical release mechanism
US7708755B2 (en) * 2005-06-02 2010-05-04 Codman & Shurtleff Inc. Stretch resistant embolic coil delivery system with combined mechanical and pressure release mechanism
US20070004973A1 (en) * 2005-06-15 2007-01-04 Tan Sharon M L Tissue treatment methods
US9463426B2 (en) * 2005-06-24 2016-10-11 Boston Scientific Scimed, Inc. Methods and systems for coating particles
JP4243268B2 (en) * 2005-09-07 2009-03-25 アドバンスド・マスク・インスペクション・テクノロジー株式会社 Pattern inspection apparatus and pattern inspection method
US8007509B2 (en) 2005-10-12 2011-08-30 Boston Scientific Scimed, Inc. Coil assemblies, components and methods
WO2007070797A2 (en) 2005-12-13 2007-06-21 Cordis Development Corporation Detachment actuator for use with medical device deployment systems
US20070142859A1 (en) * 2005-12-19 2007-06-21 Boston Scientific Scimed, Inc. Embolic coils
US8152839B2 (en) * 2005-12-19 2012-04-10 Boston Scientific Scimed, Inc. Embolic coils
US8101197B2 (en) 2005-12-19 2012-01-24 Stryker Corporation Forming coils
US20070142560A1 (en) * 2005-12-21 2007-06-21 Young-Ho Song Block copolymer particles
US7501179B2 (en) * 2005-12-21 2009-03-10 Boston Scientific Scimed, Inc. Block copolymer particles
US7947368B2 (en) * 2005-12-21 2011-05-24 Boston Scientific Scimed, Inc. Block copolymer particles
WO2007090130A2 (en) * 2006-01-30 2007-08-09 Surgica Corporation Porous intravascular embolization particles and related methods
WO2007090127A2 (en) 2006-01-30 2007-08-09 Surgica Corporation Compressible intravascular embolization particles and related methods and delivery systems
US7691124B2 (en) * 2006-01-31 2010-04-06 Codman & Shurtleff, Inc. Delivery of therapeutic devices
US7942894B2 (en) * 2006-01-31 2011-05-17 Codman & Shurtleff, Inc. Embolic device delivery system
US20070178137A1 (en) * 2006-02-01 2007-08-02 Toby Freyman Local control of inflammation
US8551135B2 (en) * 2006-03-31 2013-10-08 W.L. Gore & Associates, Inc. Screw catch mechanism for PFO occluder and method of use
CA2649702C (en) 2006-04-17 2014-12-09 Microtherapeutics, Inc. System and method for mechanically positioning intravascular implants
US8777979B2 (en) 2006-04-17 2014-07-15 Covidien Lp System and method for mechanically positioning intravascular implants
CN101500623B (en) 2006-06-15 2016-08-24 微温森公司 A kind of embolization device being made up of expandable polymer
US20070299461A1 (en) * 2006-06-21 2007-12-27 Boston Scientific Scimed, Inc. Embolic coils and related components, systems, and methods
US8062325B2 (en) 2006-07-31 2011-11-22 Codman & Shurtleff, Inc. Implantable medical device detachment system and methods of using the same
US8366720B2 (en) 2006-07-31 2013-02-05 Codman & Shurtleff, Inc. Interventional medical device system having an elongation retarding portion and method of using the same
US8414927B2 (en) 2006-11-03 2013-04-09 Boston Scientific Scimed, Inc. Cross-linked polymer particles
US20080145658A1 (en) * 2006-12-15 2008-06-19 Boston Scientific Scimed, Inc. Freeze Thaw Methods For Making Polymer Particles
KR20100015520A (en) 2007-03-13 2010-02-12 마이크로 테라퓨틱스 인코포레이티드 An implant including a coil and a stretch-resistant member
KR20100015521A (en) 2007-03-13 2010-02-12 마이크로 테라퓨틱스 인코포레이티드 An implant, a mandrel, and a method of forming an implant
US9005242B2 (en) 2007-04-05 2015-04-14 W.L. Gore & Associates, Inc. Septal closure device with centering mechanism
WO2009003049A2 (en) 2007-06-25 2008-12-31 Micro Vention, Inc. Self-expanding prosthesis
EP2266639B1 (en) 2007-12-21 2016-10-05 MicroVention, Inc. Methods for preparing hydrogel filaments for biomedical use
US20130165967A1 (en) 2008-03-07 2013-06-27 W.L. Gore & Associates, Inc. Heart occlusion devices
US20110212179A1 (en) * 2008-10-30 2011-09-01 David Liu Micro-spherical porous biocompatible scaffolds and methods and apparatus for fabricating same
US9636094B2 (en) 2009-06-22 2017-05-02 W. L. Gore & Associates, Inc. Sealing device and delivery system
US20120029556A1 (en) 2009-06-22 2012-02-02 Masters Steven J Sealing device and delivery system
AU2010298026B2 (en) * 2009-09-24 2015-11-05 Microvention, Inc. Injectable hydrogel filaments for biomedical uses
KR101745748B1 (en) * 2009-10-26 2017-06-12 마이크로벤션, 인코포레이티드 Embolization device constructed from expansile polymer
US9456823B2 (en) 2011-04-18 2016-10-04 Terumo Corporation Embolic devices
US9770232B2 (en) 2011-08-12 2017-09-26 W. L. Gore & Associates, Inc. Heart occlusion devices
US9579104B2 (en) 2011-11-30 2017-02-28 Covidien Lp Positioning and detaching implants
US9011480B2 (en) 2012-01-20 2015-04-21 Covidien Lp Aneurysm treatment coils
US9687245B2 (en) 2012-03-23 2017-06-27 Covidien Lp Occlusive devices and methods of use
WO2013158781A1 (en) 2012-04-18 2013-10-24 Microvention, Inc. Embolic devices
US10828019B2 (en) 2013-01-18 2020-11-10 W.L. Gore & Associates, Inc. Sealing device and delivery system
US9662120B2 (en) 2013-08-23 2017-05-30 Cook Medical Technologies Llc Detachable treatment device delivery system utilizing compression at attachment zone
WO2015153996A1 (en) 2014-04-03 2015-10-08 Micro Vention, Inc. Embolic devices
US9713475B2 (en) 2014-04-18 2017-07-25 Covidien Lp Embolic medical devices
JP6599361B2 (en) 2014-04-29 2019-10-30 マイクロベンション インコーポレイテッド Polymer containing an active agent
US10092663B2 (en) 2014-04-29 2018-10-09 Terumo Corporation Polymers
US9808230B2 (en) 2014-06-06 2017-11-07 W. L. Gore & Associates, Inc. Sealing device and delivery system
WO2016201250A1 (en) 2015-06-11 2016-12-15 Microvention, Inc. Expansile device for implantation
JP2020515592A (en) 2017-03-27 2020-05-28 ドン,ヨンファ Chain drug structure and its manufacturing device and storage device

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD233303A1 (en) * 1984-12-28 1986-02-26 Univ Berlin Humboldt CLOSURE BODY FOR BLOOD OBJECTS AND METHOD FOR ITS INTRODUCTION
FR2641692A1 (en) * 1989-01-17 1990-07-20 Nippon Zeon Co Plug for closing an opening for a medical application, and device for the closure plug making use thereof
US5181921A (en) * 1990-05-25 1993-01-26 Kaken Co., Ltd. Detachable balloon with two self-sealing valves
US5292332A (en) * 1992-07-27 1994-03-08 Lee Benjamin I Methods and device for percutanceous sealing of arterial puncture sites
WO1994006503A1 (en) * 1992-09-22 1994-03-31 Target Therapeutics, Inc. Detachable embolic coil assembly
US5320639A (en) * 1993-03-12 1994-06-14 Meadox Medicals, Inc. Vascular plug delivery system

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE233303C (en) * 1911-04-05
US3921632A (en) * 1974-08-16 1975-11-25 Frank M Bardani Implant device
US4900303A (en) * 1978-03-10 1990-02-13 Lemelson Jerome H Dispensing catheter and method
US4708718A (en) * 1985-07-02 1987-11-24 Target Therapeutics Hyperthermic treatment of tumors
US4994069A (en) * 1988-11-02 1991-02-19 Target Therapeutics Vaso-occlusion coil and method
US5354295A (en) * 1990-03-13 1994-10-11 Target Therapeutics, Inc. In an endovascular electrolytically detachable wire and tip for the formation of thrombus in arteries, veins, aneurysms, vascular malformations and arteriovenous fistulas
US5021059A (en) * 1990-05-07 1991-06-04 Kensey Nash Corporation Plug device with pulley for sealing punctures in tissue and methods of use
US5342394A (en) * 1990-05-16 1994-08-30 Olympus Optical Co., Ltd. Apparatus for blocking a vein branch and method of blocking a vein branch
US5108407A (en) * 1990-06-08 1992-04-28 Rush-Presbyterian St. Luke's Medical Center Method and apparatus for placement of an embolic coil
US5167624A (en) * 1990-11-09 1992-12-01 Catheter Research, Inc. Embolus delivery system and method
US5226911A (en) * 1991-10-02 1993-07-13 Target Therapeutics Vasoocclusion coil with attached fibrous element(s)
US5256146A (en) * 1991-10-11 1993-10-26 W. D. Ensminger Vascular catheterization system with catheter anchoring feature
US5290310A (en) * 1991-10-30 1994-03-01 Howmedica, Inc. Hemostatic implant introducer
US5411520A (en) * 1991-11-08 1995-05-02 Kensey Nash Corporation Hemostatic vessel puncture closure system utilizing a plug located within the puncture tract spaced from the vessel, and method of use
EP0791333B1 (en) * 1991-12-12 1999-12-01 Target Therapeutics, Inc. Detachable pusher-vasoocclusive coil assembly with interlocking coupling
US5261916A (en) * 1991-12-12 1993-11-16 Target Therapeutics Detachable pusher-vasoocclusive coil assembly with interlocking ball and keyway coupling
US5234437A (en) * 1991-12-12 1993-08-10 Target Therapeutics, Inc. Detachable pusher-vasoocclusion coil assembly with threaded coupling
US5263964A (en) * 1992-05-06 1993-11-23 Coil Partners Ltd. Coaxial traction detachment apparatus and method
US5250071A (en) * 1992-09-22 1993-10-05 Target Therapeutics, Inc. Detachable embolic coil assembly using interlocking clasps and method of use
US5312415A (en) * 1992-09-22 1994-05-17 Target Therapeutics, Inc. Assembly for placement of embolic coils using frictional placement
US5350397A (en) * 1992-11-13 1994-09-27 Target Therapeutics, Inc. Axially detachable embolic coil assembly
US5334216A (en) * 1992-12-10 1994-08-02 Howmedica Inc. Hemostatic plug

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD233303A1 (en) * 1984-12-28 1986-02-26 Univ Berlin Humboldt CLOSURE BODY FOR BLOOD OBJECTS AND METHOD FOR ITS INTRODUCTION
FR2641692A1 (en) * 1989-01-17 1990-07-20 Nippon Zeon Co Plug for closing an opening for a medical application, and device for the closure plug making use thereof
US5181921A (en) * 1990-05-25 1993-01-26 Kaken Co., Ltd. Detachable balloon with two self-sealing valves
US5292332A (en) * 1992-07-27 1994-03-08 Lee Benjamin I Methods and device for percutanceous sealing of arterial puncture sites
WO1994006503A1 (en) * 1992-09-22 1994-03-31 Target Therapeutics, Inc. Detachable embolic coil assembly
US5320639A (en) * 1993-03-12 1994-06-14 Meadox Medicals, Inc. Vascular plug delivery system

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6312407B1 (en) 1995-06-05 2001-11-06 Medtronic Percusurge, Inc. Occlusion of a vessel
US6638293B1 (en) 1996-02-02 2003-10-28 Transvascular, Inc. Methods and apparatus for blocking flow through blood vessels
US7303571B2 (en) 1996-02-02 2007-12-04 Medtronic Vascular, Inc. Methods and apparatus for blocking flow through blood vessels

Also Published As

Publication number Publication date
EP0805656A1 (en) 1997-11-12
EP0805656B1 (en) 2004-05-06
US5891155A (en) 1999-04-06
JP3625837B2 (en) 2005-03-02
CA2207667A1 (en) 1996-08-01
DE69632392T2 (en) 2004-09-16
DE69632392D1 (en) 2004-06-09
US5895411A (en) 1999-04-20
JPH11503334A (en) 1999-03-26

Similar Documents

Publication Publication Date Title
US5895411A (en) Embolizing system
US5443478A (en) Multi-element intravascular occlusion device
JP3856841B2 (en) Embolization device for placement in blood vessels
EP1207791B1 (en) Controlled injection of liquid embolic composition
EP0865772B1 (en) Catheter deliverable thrombogenic apparatus
EP0986334B1 (en) Vasoocclusive device including asymmetrical pluralities of fibers
JP3132806B2 (en) Liquid-like coil with secondary shape
US20040111112A1 (en) Method and apparatus for retaining embolic material
US10517605B2 (en) Embolic device, an apparatus for embolizing a target vascular site and a method thereof
WO2005016186A1 (en) System for delivering an implant utilizing a lumen reducing member
JP2003511188A (en) Filamentary embolic device with expansion element
CN115670566A (en) Related systems and methods for vessel occlusion
Henkes et al. A device for fast mechanical clot retrieval from intracranial arteries (Phenox clot retriever)
US20060085028A1 (en) Vessel occlusion system
Coley et al. Endovascular occlusion with a new mechanical detachable coil.
EP1933927A2 (en) Methods and devices for drug eluding embolization
Bilbao et al. Platinum Wire Emholization of an Intrahepatic Arterioportal Fistula.
RU2694333C1 (en) Device for embolisation of a blood vessel
Tuite et al. Coils, Occluders, and Plugs
Cross III et al. Microcoils in Neuroembolization

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): CA JP

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2207667

Country of ref document: CA

Ref country code: CA

Ref document number: 2207667

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1996902111

Country of ref document: EP

ENP Entry into the national phase

Ref country code: JP

Ref document number: 1996 522873

Kind code of ref document: A

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 1996902111

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1996902111

Country of ref document: EP